Drug Trial Radar · NCT01324284
Comparative Study of Lubiprostone and PEG Preparation Versus Conventional PEG Preparation for Colonoscopy
Last checked: Nov 19, 2026Latest source record: Apr 5, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
442
Actual
Start
Mar 2011
Primary completion
Jun 2011
Study completion Jun 2011
Sponsor
- Lead sponsor
- Asian Institute of Gastroenterology, IndiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 29, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Lubiprostone as an adjunct to the standard bowel preparation regime the quality of bowel preparation can be improved for a good colonoscopic examination without missing lesions and complications.
Conditions
- Colorectal Carcinoma
Interventions
LubiprostoneDrug
Lubiprostone is a chloride channel activator approved by the Food and Drug Administration for the treatment of chronic constipation. A randomized, double-blind, parallel-group, placebo-controlled study evaluating the effect of lubiprostone on gastric function showed slowed gastric emptying and increased small bowel and colonic transit time. Peak plasma concentration was shown to be around 1.14 hours, with a majority of the drug excreted in the urine within 48 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Quality of bowel preparation in Same day Low volume PEG with placebo versus same day low volume PEG with LubiprostoneTime frame: 2 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.